olivLaw · US equity research
3M Company MMM
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
3M Company is a diversified technology company with three segments: Safety and Industrial, Transportation and Electronics and Consumer. Net sales were 24.948 bn USD in fiscal 2025 and 19.114 bn USD in the first nine months of 2026. Adjusted EPS guidance for 2026 was raised to 9.10-9.15 USD, which could reflect productivity gains if the trend holds.
At the close of 30 Oct 2026, 3M Company (MMM) stock was 174.34 USD (−1.70% on the day), with market capitalisation 90.1 bn USD, P/E 26.0 on diluted EPS of 6.71 USD over the last 12 months, dividend yield 1.76%, beta 0.97, 52-week range 141.20–183.78 USD. Latest reported quarter (Q3 2026): revenue of 6.6 bn USD (+1.0% YoY), net income of 1.4 bn USD (+64.6% YoY), diluted EPS 2.63 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.5
- strong (55–70)
- Bollinger (20, 2)
- 156.57 – 179.10
- in the upper half of the band · %B 0.79 · band width 13.4%
- SMA 50 / 200
- 168.47 / 161.08
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 2.21 / 1.13
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +6.2% | −0.9% | +7.1 pp | — |
| 3 months | −1.1% | +1.2% | −2.3 pp | — |
| 6 months | +22.3% | +4.8% | +17.5 pp | — |
| Year to date | +8.9% | +10.7% | −1.8 pp | — |
| 1 year | +4.7% | +11.1% | −6.4 pp | +17.0% |
| 3 years | +129.3% | +80.7% | +48.5 pp | +3.8% |
| 5 years | +16.7% | +64.6% | −47.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.0 bn | 6.0 bn | 6.3 bn | 6.5 bn | 6.1 bn | 6.0 bn | 6.5 bn | 6.6 bn |
| Cost of revenue | 3.7 bn | 3.5 bn | 3.6 bn | 3.8 bn | 4.1 bn | 3.6 bn | 3.8 bn | 3.8 bn |
| SG&A | 899.0 m | 945.0 m | 1.3 bn | 820.0 m | 965.0 m | 744.0 m | 1.1 bn | 921.0 m |
| Operating income | 1.1 bn | 1.2 bn | 1.1 bn | 1.4 bn | 796.0 m | 1.4 bn | 984.0 m | 1.6 bn |
| Depreciation & amortisation | 322.0 m | 290.0 m | 290.0 m ≈ | 298.0 m ≈ | 430.0 m | 326.0 m | 335.0 m ≈ | 336.0 m ≈ |
| Interest expense | 252.0 m | 255.0 m | 237.0 m | 232.0 m | 222.0 m | 214.0 m | 202.0 m | 217.0 m |
| Pre-tax income | 759.0 m | 1.4 bn | 923.0 m | 1.1 bn | 758.0 m | 878.0 m | 1.1 bn | 1.7 bn |
| Income tax | 33.0 m | 265.0 m | 245.0 m | 308.0 m | 185.0 m | 221.0 m | 183.0 m | 261.0 m |
| Net income | 728.0 m | 1.1 bn | 723.0 m | 834.0 m | 577.0 m | 653.0 m | 933.0 m | 1.4 bn |
| Diluted EPS | 1.33 | 2.04 | 1.34 | 1.55 | 1.07 ≈ | 1.23 | 1.78 | 2.63 |
| Operating cash flow | 1.8 bn | -79.0 m | -954.0 m ≈ | 1.8 bn ≈ | 1.6 bn | 574.0 m | 986.0 m ≈ | 486.0 m ≈ |
| Capex | 291.0 m | 236.0 m | 208.0 m ≈ | 218.0 m ≈ | 248.0 m | 225.0 m | 223.0 m ≈ | 256.0 m ≈ |
| Dividends paid | 378.0 m | 396.0 m | 390.0 m ≈ | 389.0 m ≈ | 387.0 m | 412.0 m | 401.0 m ≈ | 403.0 m ≈ |
| Share repurchases | 705.0 m | 1.3 bn | 953.0 m ≈ | 472.0 m ≈ | 552.0 m | 2.0 bn | 994.0 m ≈ | 232.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 88 percentile of its own 40-quarter history (min 8.0, median 18.1, max 60.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.8 bn | 32.1 bn | 32.2 bn | 35.4 bn | 26.2 bn | 24.6 bn | 24.6 bn | 24.9 bn |
| Revenue YoY | +3.5% | −1.9% | +0.1% | +9.9% | −26.0% | −5.9% | −0.1% | +1.5% |
| Net income | 5.3 bn | 4.5 bn | 5.4 bn | 5.9 bn | 5.8 bn | -7.0 bn | 4.2 bn | 3.3 bn |
| Net income YoY | +10.1% | −15.6% | +20.6% | +8.7% | −2.4% | −221.1% | unavailable | −22.1% |
| Diluted EPS | 8.89 | 7.72 | 9.36 | 10.12 | 10.18 | -12.63 | 7.55 | 6.00 |
| Diluted EPS YoY | +12.1% | −13.2% | +21.2% | +8.1% | +0.6% | −224.1% | unavailable | −20.5% |
| net % | 16.3% | 14.1% | 16.9% | 16.7% | 22.1% | -28.4% | 17.0% | 13.0% |
| Free cash flow | 4.9 bn | 5.4 bn | 6.6 bn | 5.9 bn | 3.8 bn | 5.1 bn | 638.0 m | 1.4 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.2 bn USD
- Financial debt
- 12.6 bn USD
- Net debt
- 7.4 bn USD
- Equity
- 4.7 bn USD
- Total assets
- 37.7 bn USD
- Debt / equity
- 2.65x
- Current ratio
- 1.71x
- ROE
- 75.2%
- ROA
- 8.4%
- FCF margin
- 5.6%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 32.2 bn | 35.4 bn | 26.2 bn | 24.6 bn | 24.6 bn | 24.9 bn | SEC (XBRL)· 03 Feb 2026verified |
| Cost of revenue | 16.6 bn | 18.8 bn | 15.9 bn | 15.0 bn | 14.4 bn | 15.0 bn | SEC (XBRL)· 03 Feb 2026verified |
| Gross profit | 15.6 bn ≈ | 16.6 bn ≈ | 10.3 bn ≈ | 9.6 bn ≈ | 10.1 bn ≈ | 10.0 bn ≈ | SEC (XBRL)· 03 Feb 2026derived |
| Research & development | 1.1 bn | 1.2 bn | 800.0 m | 700.0 m | 700.0 m | — | SEC (XBRL)· 05 Feb 2025verified |
| SG&A | 6.9 bn | 7.2 bn | 7.2 bn | 19.2 bn | 4.2 bn | 4.0 bn | SEC (XBRL)· 03 Feb 2026verified |
| Operating income | 7.2 bn | 7.4 bn | 4.4 bn | -10.7 bn | 4.8 bn | 4.6 bn | SEC (XBRL)· 03 Feb 2026verified |
| Depreciation & amortisation | 1.9 bn | 1.9 bn | 1.8 bn | 2.0 bn | 1.4 bn | 1.3 bn | SEC (XBRL)· 03 Feb 2026verified |
| EBITDA | 9.1 bn ≈ | 9.3 bn ≈ | 6.2 bn ≈ | -8.7 bn ≈ | 6.2 bn ≈ | 5.9 bn ≈ | SEC (XBRL)· 03 Feb 2026derived |
| Interest expense | 529.0 m | 488.0 m | 462.0 m | 942.0 m | 1.2 bn | 946.0 m | SEC (XBRL)· 03 Feb 2026verified |
| Pre-tax income | 6.8 bn | 7.2 bn | 4.2 bn | -11.3 bn | 4.8 bn | 4.2 bn | SEC (XBRL)· 03 Feb 2026verified |
| Income tax | 1.3 bn | 1.3 bn | 188.0 m | -2.9 bn | 804.0 m | 1.0 bn | SEC (XBRL)· 03 Feb 2026verified |
| Net income | 5.4 bn | 5.9 bn | 5.8 bn | -7.0 bn | 4.2 bn | 3.3 bn | SEC (XBRL)· 03 Feb 2026verified |
| Diluted EPS | 9.36 | 10.12 | 10.18 | -12.63 | 7.55 | 6.00 | SEC (XBRL)· 03 Feb 2026verified |
| Weighted average diluted shares | 582.2 m | 585.3 m | 567.6 m | 553.9 m | 552.4 m | 541.3 m | SEC (XBRL)· 03 Feb 2026verified |
| Dividend per share | 5.88 | 5.92 | 5.96 | 6.00 | 3.61 | 2.92 | SEC (XBRL)· 03 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 4.6 bn | 4.6 bn | 3.7 bn | 5.9 bn | 5.6 bn | 5.2 bn | SEC (XBRL)· 03 Feb 2026verified |
| Receivables | 4.7 bn | 4.7 bn | 4.5 bn | 3.6 bn | 3.2 bn | 3.5 bn | SEC (XBRL)· 03 Feb 2026verified |
| Inventories | 4.2 bn | 5.0 bn | 5.4 bn | 3.9 bn | 3.7 bn | 3.7 bn | SEC (XBRL)· 03 Feb 2026verified |
| Current assets | 15.0 bn | 15.4 bn | 14.7 bn | 16.4 bn | 15.9 bn | 16.4 bn | SEC (XBRL)· 03 Feb 2026verified |
| Property, plant & equipment, net | 9.4 bn | 9.4 bn | 9.2 bn | 7.7 bn | 7.4 bn | 7.1 bn | SEC (XBRL)· 03 Feb 2026verified |
| Goodwill | 13.8 bn | 13.5 bn | 6.3 bn | 6.4 bn | 6.3 bn | 6.4 bn | SEC (XBRL)· 03 Feb 2026verified |
| Intangibles (excl. goodwill) | 5.8 bn | 5.3 bn | 4.7 bn | 1.3 bn | 1.2 bn | 1.1 bn | SEC (XBRL)· 03 Feb 2026verified |
| Total assets | 47.3 bn | 47.1 bn | 46.5 bn | 50.6 bn | 39.9 bn | 37.7 bn | SEC (XBRL)· 03 Feb 2026verified |
| Accounts payable | 2.6 bn | 3.0 bn | 3.2 bn | 2.8 bn | 2.7 bn | 2.7 bn | SEC (XBRL)· 03 Feb 2026verified |
| Short-term debt | 806.0 m | 1.3 bn | 1.9 bn | 2.9 bn | 1.9 bn | 1.7 bn | SEC (XBRL)· 03 Feb 2026verified |
| Long-term debt | 18.0 bn | 16.1 bn | 14.0 bn | 13.1 bn | 11.1 bn | 10.9 bn | SEC (XBRL)· 03 Feb 2026verified |
| Current liabilities | 7.9 bn | 9.0 bn | 9.5 bn | 15.3 bn | 11.3 bn | 9.6 bn | SEC (XBRL)· 03 Feb 2026verified |
| Total liabilities | 34.4 bn | 32.0 bn | 31.7 bn | 45.7 bn | 36.0 bn | 33.0 bn | SEC (XBRL)· 03 Feb 2026verified |
| Equity | 12.9 bn | 15.1 bn | 14.8 bn | 4.9 bn | 3.9 bn | 4.7 bn | SEC (XBRL)· 03 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.1 bn | 7.5 bn | 5.6 bn | 6.7 bn | 1.8 bn | 2.3 bn | SEC (XBRL)· 03 Feb 2026verified |
| Capex | 1.5 bn | 1.6 bn | 1.7 bn | 1.6 bn | 1.2 bn | 910.0 m | SEC (XBRL)· 03 Feb 2026verified |
| Free cash flow | 6.6 bn ≈ | 5.9 bn ≈ | 3.8 bn ≈ | 5.1 bn ≈ | 638.0 m ≈ | 1.4 bn ≈ | SEC (XBRL)· 03 Feb 2026derived |
| Investing cash flow | -580.0 m | -1.3 bn | -1.0 bn | -1.2 bn | -3.2 bn | 1.4 bn | SEC (XBRL)· 03 Feb 2026verified |
| Financing cash flow | -5.3 bn | -6.1 bn | -5.4 bn | -3.1 bn | 1.1 bn | -4.0 bn | SEC (XBRL)· 03 Feb 2026verified |
| Dividends paid | 3.4 bn | 3.4 bn | 3.4 bn | 3.3 bn | 2.0 bn | 1.6 bn | SEC (XBRL)· 03 Feb 2026verified |
| Share repurchases | 368.0 m | 2.2 bn | 1.5 bn | 33.0 m | 1.8 bn | 3.3 bn | SEC (XBRL)· 03 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 50 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: 90.1 bn USD
Key indicators
Coverage and freshness
Score by group
- Returns86
- Quality72
- Growth0
- Valuation49
- Balance sheet49
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 38.37 – 287.51 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)60.99 – 108.14 (Mid 78.87)WACC 8.7% · starting FCFF 3.4 bn USD · terminal value share of EV 74%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 30.1%
- Peers: EV/EBITDA139.29 – 168.19 (Mid 154.78)4 companies used · median multiple 14.6x · quartiles 13.3x – 15.8xBDX, BSX, RMD, SYK
- Peers: P/E157.52 – 287.51 (Mid 213.00)6 companies used · median multiple 31.7x · quartiles 23.5x – 42.8xBDX, BSX, DXCM, RMD, SYK, WST
- Dividend discount (DDM)38.37 – 51.60 (Mid 44.01)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 50/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 28.4% | 100 (vs peers) | 10% |
| Net margin · Quality | 14.0% | 33 (vs peers) | 6% |
| FCF conversion · Quality | 75.7% | 65 (on a fixed band) | 6% |
| Revenue CAGR 3Y · Growth | -1.6% | 0 (on a fixed band) | 8% |
| EPS CAGR 3Y · Growth | -16.2% | 0 (on a fixed band) | 8% |
| Net debt / EBITDA · Balance sheet | 1.6x | 40 (vs peers) | 10% |
| Interest coverage · Balance sheet | 5.5x | 62 (on a fixed band) | 6% |
| Current ratio · Balance sheet | 1.4x | 51 (on a fixed band) | 4% |
| P/E (TTM) · Valuation | 26.0x | 67 (vs peers) | 10% |
| EV/EBITDA · Valuation | 16.3x | 40 (vs peers) | 10% |
| FCF yield · Valuation | 3.0% | 37 (on a fixed band) | 8% |
| Shareholder yield (distributions) · Returns | 6.0% | 85 (on a fixed band) | 6% |
| Payout ratio (FCF) · Returns | 59.9% | 86 (on a fixed band) | 4% |
Score groups
- Balance sheet49/100 · 3/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality72/100 · 3/3 factors with a value
- Returns86/100 · 2/2 factors with a value
- Valuation49/100 · 3/3 factors with a value
Memo
3M COMPANY (MMM). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 24.9 bn USD in 2025; YoY growth 1.5%; net margin 14.0%; ROE 80.8%; net debt/EBITDA 1.6x.
The estimated value range is 100.14–138.17 USD per share (median of 4 methods, agreement: low); assumptions are illustrative. Against the central value of 116.82 USD, the price of 174.34 USD leaves a potential of -33.0% (value / price − 1) and a margin of safety of -49.2% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 50/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- ROIC: 28.4%
- Shareholder yield (distributions): 6.0%
- Payout ratio (FCF): 59.9%
What contradicts it
- Revenue CAGR 3Y: -1.6%
- EPS CAGR 3Y: -16.2%
- The price is above the estimated value range
- The valuation methods diverge
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 6 companies
Only companies with a capitalisation between 11.3 bn and 725.7 bn (within 8× of the company's); 107 of the vertical were left out.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 111.1 bn | 31.1 | 16.0% | 13.8% | +11.2% | −18% / +8% |
| MMM3m Company | 90.1 bn | 26.0 | 80.8% | 14.0% | +1.5% | +5% / +129% |
| BSXBoston Scientific Corporation | 60.8 bn | 17.0 | 15.5% | 17.5% | +19.9% | −58% / −18% |
| BDXBecton, Dickinson And Company | 53.9 bn | 59.7 | 3.8% | 4.0% | +8.2% | +41% / −0% |
| RMDResMed Inc. | 32.3 bn | 20.9 | 26.4% | 27.8% | +9.9% | −7% / +63% |
| DXCMDexcom, Inc. | 30.7 bn | 32.4 | 37.7% | 19.4% | +15.6% | +41% / −7% |
| WSTWest Pharmaceutical Services, Inc. | 28.7 bn | 46.3 | 21.2% | 18.8% | +6.3% | +46% / +30% |
1- and 3-year price returns: for MMM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 98.67 Total return -42% · Per year -42% | 174.99 Total return 2% · Per year 2% | 264.32 Total return 54% · Per year 54% |
| 3 years | 84.44 Total return -48% · Per year -20% | 169.54 Total return 2% · Per year 1% | 282.77 Total return 69% · Per year 19% |
| 5 years | 72.25 Total return -53% · Per year -14% | 164.25 Total return 3% · Per year 1% | 302.50 Total return 85% · Per year 13% |
- Exit P/E± 42.38
- Net margin± 29.67
- Annual revenue growth± 25.86
- Annual dilution± 2.49
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
3M Company is a diversified technology company with three segments: Safety and Industrial, Transportation and Electronics and Consumer. Net sales were 24.948 bn USD in fiscal 2025 1 and 19.114 bn USD in the first nine months of 2026 2. Adjusted EPS guidance for 2026 was raised to 9.10-9.15 USD 3, which could reflect productivity gains if the trend holds.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- PFAS liabilities and litigationhigh
PFAS-related actions, including class-action settlements, could affect results, cash flows and financial position 1.
- Tariffs and geopoliticshigh
Trade tensions and tariff measures could have a significant adverse effect on costs and revenues 1.
- Currency exchangemedium
A significant strengthening of the US dollar could reduce reported revenues and affect projected growth 1.
- Execution of transformation programmedium
Implementing new systems and the productivity plan may face delays or unexpected costs 12.
- Demand in autos and electronicslow
Continued weakness in these sectors could limit segment sales growth 2.
Investment thesis
What would need to be true (bull case)
- If demand from data centers and semiconductors develops as the announced partnerships suggest, the company could accelerate sales growth 3.
- Productivity programs and cost control could keep operating margins at elevated levels 23.
- A broad portfolio and strong patents could support new product launches with rapid adoption 1.
What would break the thesis
What to watch
- Development of adjusted EPS guidance and free cash flowQ4 2026
- PFAS-related expenses and payments under the PWS Settlement2027
- Sales development for data center products after the Amazon agreement2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
3M is a diversified technology company with global operations across three segments: Safety and Industrial, Transportation and Electronics and Consumer 1. At December 31, 2025 it employed about 60,500 full-time equivalents 1. Products reach customers through varied channels, from distributors to direct and e-commerce sales 1.
In 2025 about 56 percent of revenues came from outside the United States 1, so results depend heavily on currency movements and international trade. The company completed its exit from PFAS manufacturing at the end of 2025 and continues treatment and remediation of these substances 12. Organizational and segment profit metrics were adjusted in 2026 2.
Segments
Safety and Industrial
This segment includes abrasives, industrial adhesives, personal safety and roofing granules 1. In the first nine months of 2026 growth was supported by industrial, safety and semiconductor demand 2.
Market context
3M's end markets are sensitive to industrial cycles, auto production and demand for data center and semiconductor equipment 12. Pricing pressure, tariffs and geopolitical uncertainty have led producers to adjust capacity, causing supply constraints and inflation in raw materials 1.
Demand for protection solutions, optical connectivity and advanced displays could support medium-term growth if innovation investments translate into customer adoption 3. A continued slowdown in autos and consumer electronics remains a market risk 2.
Trends
- Tariffs and international tradeheadwind
Tariffs and trade measures have raised production costs and complicated long-term investment planning 1. Compliance with changing rules requires significant time and resources 1.
- Data centers and semiconductorstailwind
Demand for optical connectivity and semiconductor materials has become a growth driver, as the Amazon relationship and the GSEO collaboration show 3.
- PFAS exitmixed
Exiting PFAS manufacturing at the end of 2025 created transition and remediation costs, but could lower long-term costs if substitutes are available 12.
- Productivity and transformationtailwind
Productivity programs and structural transformation supported margins in 2026 23, though transformation costs appeared as a special item in reporting 2.
Competitive position
3M competes with other technologically oriented manufacturers, and product success depends on trademarks, patents and trade secrets 1. The company believes these assets provide an important competitive advantage in new product introductions 1.
Competition appears through competitive conditions and customer preferences, as well as the ability to launch accepted new products 2. Relationships with distributors and channel partners are a differentiating factor 1.
- Other innovation-oriented materials and technology manufacturers
The SEC sources refer to technologically oriented competitors in general, without naming specific companies 1.
- Optical connectivity and data center component suppliers
Competition in this area is cited as part of competitive conditions, without company names in the sources reviewed 2.
- Display and electronics materials producers
The joint laboratory with BOE points to an area of both competition and collaboration in the same ecosystem 3.
- Personal protective equipment manufacturers
Respiratory and hearing protection is a product line exposed to direct competition 13.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report20 Oct 2026
- Current report20 Oct 2026Results of operations · Financial statements and exhibits
- Current report19 Oct 2026Regulation FD disclosure
- Current report10 Sept 2026Other events · Financial statements and exhibits
- Current report19 Aug 2026Material agreement · Termination of a material agreement · Creation of a direct financial obligation
- Quarterly report21 Jul 2026
- Current report21 Jul 2026Results of operations · Financial statements and exhibits
- Current report08 Jun 2026Departure or appointment of officers · Financial statements and exhibits
- Current report13 May 2026Shareholder vote
- Current report06 May 2026Material agreement · Creation of a direct financial obligation
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / 3M Company · 03 Feb 2026
- [2] Form 10-Q, quarter ended 2026-09-30 · SEC / 3M Company · 20 Oct 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / 3M Company · 20 Oct 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.